FR0004163111
© Globe Newswire
27.11.2025
GNFT
LISTED
EURONEXT
GENFIT Announces Appointment of new Chief Medical Officer
News Preview
GENFIT today announced the appointment of Dr. Pejvack Motlagh, the new Chief Medical Officer of GENFIT...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
GNFT
LISTED
EURONEXT
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its third quarter 2025 financial results1 and provided a corporate update....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
GNFT
LISTED
EURONEXT
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
News Preview
GENFIT announces the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Global Selec...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
10.11.2025
GNFT
LISTED
EURONEXT
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces a research collaboration with EVerZom to expand its Acute-On-Chronic Lier Fail...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
10.11.2025
GNFT
LISTED
EURONEXT
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today presents promising new preclinical data in ACLF at The Liver Meeting® 2025 with nitazoxa...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2025
GNFT
LISTED
EURONEXT
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), October 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its participation at the upcoming American Association for the Study of Liver D...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
GNFT
LISTED
EURONEXT
GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update
News Preview
Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); September 22, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half 2025 financial results and provided a corporate up...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
GNFT
LISTED
EURONEXT
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its decision to discontinue its VS-01 program in ACLF (Acute-on-Chronic Liver...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2025
GNFT
LISTED
EURONEXT
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2025
GNFT
LISTED
EURONEXT
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
GNFT
LISTED
EURONEXT
GENFIT Reports First Quarter 2025 Financial Information
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2025 and revenues for the first three...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.05.2025
GNFT
LISTED
EURONEXT
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen’s Iqirvo®1 has been granted pricing and reimbursement in Italy for Prima...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
14.05.2025
GNFT
LISTED
EURONEXT
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the publication of its 2025 Extra-Financial Performance Report (fiscal year 2024)....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.04.2025
GNFT
LISTED
EURONEXT
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the filing of its 2024 Universal Registration Document with the Autorité des marc...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.04.2025
GNFT
LISTED
EURONEXT
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen will be presenting data from its late-breaking abstract on elafibranor...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
GNFT
LISTED
EURONEXT
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
News Preview
Lille, France; Cambridge, MA; Zurich, Switzerland; April 24, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended December 31, 2024. A summary of the consolidated financ...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
GNFT
LISTED
EURONEXT
GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), is pleased to announce the successful completion of its royalty financing transac...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.03.2025
GNFT
LISTED
EURONEXT
Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), today announces the results of the bondholders’ vote at the general meeting of th...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.02.2025
GNFT
LISTED
EURONEXT
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 21, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option Agreements with 2025 OCEANEs holders and the con...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.02.2025
GNFT
LISTED
EURONEXT
GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 14, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the amendment of the final terms of the 2025 OCEANEs repurchase proposal and t...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.02.2025
GNFT
LISTED
EURONEXT
GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the final terms of the 2025 OCEANEs repurchase proposal and the consent fee th...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.02.2025
GNFT
LISTED
EURONEXT
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 6, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today outlines the design of new clinical trials within its Acute on-Chronic Liver Failure (ACL...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.01.2025
GNFT
LISTED
EURONEXT
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 30, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), today announces that it has entered into a non-dilutive capped royal...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2025
GNFT
LISTED
EURONEXT
GENFIT Announces 2025 Financial Calendar
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
GNFT
LISTED
EURONEXT
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
News Preview
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 13 janvier 2025 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui le bilan semestriel du contra...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
GNFT
LISTED
EURONEXT
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 13, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today provided a corporate update ahead of The Liver Meeting 2024®2....
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2024
GNFT
LISTED
EURONEXT
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the European Commission has conditionally approved Iqirvo®1 (...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2024
GNFT
LISTED
EURONEXT
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
News Preview
Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); September 19, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half-year 2024 financial results and provided a corpor...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2024
GNFT
LISTED
EURONEXT
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2024
GNFT
LISTED
EURONEXT
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusion of NIS2+® as a key tool for detecting at-risk MASH1 in th...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2024
GNFT
LISTED
EURONEXT
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 10, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the achievement of a historic corporate milestone: the U.S. Food and Dr...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.05.2024
GNFT
LISTED
EURONEXT
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence at the EASL Congress™ 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2024
GNFT
LISTED
EURONEXT
GENFIT: May 22, 2024 Combined Shareholders Meeting Results
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
